Weaknesses In Gilead's Remdesivir Trial Designs Unlikely to Impact Approval Prospects In US

Urgency of the COVID-19 crisis, political pressure, and trends in FDA reviews all point in favor of Gilead, despite the company's decision to conduct open-label Phase III trials for remdesivir and only one study with a control arm.

Gilead sign at headquarters in Silicon Valley. Gilead Sciences, Inc. is an American biotechnology company that researches, develops and commercializes drugs - Foster City, California, USA - 2020
Gilead said speed and a desire to test varying dosing regimens influenced their trial design decisions. • Source: Shutterstock

Gilead Sciences Inc.’s late-stage trial designs for remdesivir, an antiviral being tested in COVID-19, will create challenges to determining the drug’s efficacy and safety in treating the virus. Both of their pivotal trials are open label and only one has a control arm. But experts say those limitations are unlikely to stand in the way of approval of the treatment by the US Food and Drug Administration.

Political pressure, the nature of an urgent pandemic situation, and the FDA’s general willingness over the past few years to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Approval Standards

More from Pathways & Standards